42,000 Shares in Bristol Myers Squibb Company $BMY Acquired by Barbara Oil Co.

Key Points

• Barbara Oil Co. acquired 42,000 Bristol Myers Squibb shares worth approximately $2.42 million in the second quarter. Institutional investors and hedge funds collectively own 76.41% of BMY.
• Bristol Myers Squibb exceeded quarterly expectations, reporting $2.04 in EPS and $12.97 billion in revenue, while revenue rose 5.7% year over year. The company also pays a quarterly dividend of $0.63 per share, yielding about 3.8% annually.
• Analyst sentiment remains a Moderate Buy, though ratings are mixed, with price targets ranging from $66.06 on average to $75. Generic competition remains a key risk as investors assess whether Eliquis and newer pipeline products can offset declines in legacy medicines.

Barbara Oil Co. bought a new stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 42,000 shares of the biopharmaceutical company's stock, valued at approximately $2,420,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Davis Asset Management L.P. acquired a new position in shares of Bristol Myers Squibb in the 2nd quarter valued at about $27,000. Swiss RE Ltd. acquired a new stake in Bristol Myers Squibb during the 4th quarter worth approximately $25,000. Physician Wealth Advisors Inc. raised its holdings in Bristol Myers Squibb by 73.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 202 shares during the period. Darwin Wealth Management LLC purchased a new position in Bristol Myers Squibb in the second quarter valued at approximately $25,000. Finally, Addison Advisors LLC acquired a new position in Bristol Myers Squibb during the second quarter valued at approximately $32,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Bristol Myers Squibb Stock Up 0.1%

Shares of NYSE BMY opened at $67.06 on Monday. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $68.64. The firm has a market cap of $136.98 billion, a price-to-earnings ratio of 14.77, a PEG ratio of 0.17 and a beta of 0.22. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The stock's 50-day simple moving average is $60.55 and its 200-day simple moving average is $59.39.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating analysts' consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The firm had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. During the same quarter in the prior year, the business posted $1.46 earnings per share. Bristol Myers Squibb's revenue for the quarter was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, equities analysts anticipate that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were paid a dividend of $0.63 per share. The ex-dividend date was Thursday, July 2nd. This represents a $2.52 annualized dividend and a yield of 3.8%. Bristol Myers Squibb's dividend payout ratio is presently 55.51%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Truist Financial reissued a "buy" rating and issued a $70.00 price objective (up from $65.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Guggenheim reaffirmed a "buy" rating and set a $75.00 price target (up from $72.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. UBS Group downgraded Bristol Myers Squibb from a "buy" rating to a "neutral" rating in a report on Wednesday, August 5th. BMO Capital Markets reissued a "market perform" rating on shares of Bristol Myers Squibb in a research report on Monday, July 27th. Finally, Raymond James Financial initiated coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a "strong-buy" rating on the stock. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Bristol Myers Squibb has an average rating of "Moderate Buy" and an average target price of $66.06.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb plans to invest approximately $2.3 billion in a new Houston manufacturing facility, part of a broader $40 billion U.S. investment commitment. The project reinforces BMY’s confidence in domestic production capacity and could support long-term operational growth. Bristol-Myers Squibb Bets $2.3 Billion on Texas
• Positive Sentiment: BMY is collaborating with Chai Discovery on artificial-intelligence-driven antibody discovery. The partnership could help identify novel therapeutic candidates more efficiently and strengthens the company’s efforts to modernize its drug-development platform. Chai Discovery Collaboration
• Positive Sentiment: The company is launching a Phase 1 study of an early Alzheimer’s disease antibody. Although the program remains highly experimental, it adds another potential long-term growth opportunity to BMY’s pipeline. Early Alzheimer’s Antibody Study
• Positive Sentiment: Strong Eliquis performance is helping offset declines in BMY’s older products facing generic pressure, supporting a more favorable 2026 revenue outlook. Elevated call-option activity also signals increased bullish interest, though it is not a fundamental guarantee. Eliquis and Legacy Portfolio Analysis
• Neutral Sentiment: Early clinical work on navlimetostat shows continued pipeline activity, but the Phase 1-stage program has not yet produced efficacy data that would materially change near-term earnings expectations. Navlimetostat Study Update
• Negative Sentiment: Generic competition remains a key risk for BMY’s legacy portfolio. Investors must determine whether Eliquis growth and newer pipeline assets can replace revenue lost as established medicines face erosion. Legacy Portfolio Erosion Analysis

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source